Solasia Pharma K K : Partner, Isofol Announces Global Phase III AGENT Study for arfolitixorin(SP-05) Completed Recruitment of Japanese Patients

To: All Concerned Parties	May 6, 2021
Company Name: Solasia Pharma K.K.
Representative:	Yoshihiro Arai, President & CEO
(Code number:	4597, TSE Mothers Section)
Contact:	Toshio Miyashita, CFO, Director
Tel:	81-3-5843-8049
URL:	https://solasia.co.jp/en/

Solasia's Partner, Isofol Announces Global Phase III AGENT Study for

arfolitixorin(SP-05) Completed Recruitment of Japanese Patients

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the global phase III AGENT study for arfolitixorin(SP-05) has completed the recruitment of Japanese patients in accordance with the regulatory requirements by the PMDA (the Japanese Medicines Agency) to reach market approval in Japan.

For more information, please refer to the following URL link to Isofol´s website. https://isofolmedical.com/

###